Saturday 17 October 2026
Export HALO’s income statement to Excel — free account
Halozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
121.84
0.33
+0.27%
Follow HALO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
22.24 | 22.13 | 25.79 | 15.00 |
+8 more quarters Free account |
P/S ratio |
5.52 | 5.06 | 5.77 | 6.92 | |
P/FCF ratio |
11.39 | 11.44 | 12.51 | 11.62 | |
P/Operating CF |
38.10 | 42.40 | 36.82 | 48.14 | |
P/B ratio |
63.95 | 34.77 | 165.22 | 17.06 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
6.67 | 6.27 | 7.72 | 7.57 | |
EV/EBITDA |
15.43 | 15.27 | 19.20 | 11.46 | |
EV/Operating CF |
13.55 | 13.97 | 16.54 | 15.39 | |
EV/FCF |
13.76 | 14.17 | 16.72 | 12.72 | |
Quick Ratio |
1.99 | 2.14 | 3.30 | 1.25 | |
Current Ratio |
2.71 | 2.76 | 4.66 | 1.59 | |
Net Debt/EBITDA |
5.93 | 8.28 | (31.07) | 3.37 | |
Debt/Assets |
83.29% | 80.24% | 84.85% | 68.01% | |
Debt/Equity |
14.95 | 9.76 | 43.89 | 3.00 | |
Asset Turnover |
0.72 | 0.62 | 0.61 | 0.57 | |
Operating CF/Net income |
1.05 | 1.20 | (1.55) | 1.02 | |
Capex/Depreciation |
(0.12) | (0.10) | (15.78) | 20.34 | |
Interest Coverage |
51.48 | 33.50 | (18.91) | 50.73 | |
Research and Development Expense of Revenue |
5.75% | 6.79% | 70.12% | 4.87% | |
Selling, General and Administrative Expense of Revenue |
11.85% | 15.36% | 17.05% | 13.01% | |
Intangible Assets out of Total Assets |
0.58 | 0.57 | 0.62 | 0.34 | |
Share Based Compensation of Revenue |
3.68% | 4.42% | 3.67% | 3.43% | |
Graham Net Nets |
(0.16) | (0.19) | (0.20) | (0.05) | |
Graham Number |
9.85 | 11.05 | 4.89 | 21.75 | |
Earnings Yield |
4.50% | 4.52% | 3.88% | 6.67% | |
Free Cash Flow Yield |
8.78% | 8.74% | 7.99% | 8.60% | |
Revenue per Share |
4.10 | 3.19 | 3.77 | 3.02 | |
Operating CF per Share |
2.05 | 1.52 | 1.83 | 1.52 | |
Capex per Share |
(0.04) | (0.03) | (3.76) | 3.80 | |
Free Cash Flow per Share |
2.02 | 1.49 | (1.93) | 5.33 | |
Cash per Share |
1.97 | 2.70 | 1.19 | 5.99 | |
Shareholders Equity per Share |
1.22 | 1.86 | 0.41 | 4.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.22 | 1.86 | 0.41 | 4.30 | |
Free Cash Flow |
236.72 | 176.34 | (231.27) | 624.44 | |
Working Capital |
588.59 | 639.83 | 648.12 | 491.52 | |
Capital Expenditures |
(4.17) | (3.74) | (450.30) | 445.84 | |
Net Current Asset Value |
(1,500.84) | (1,450.05) | (1,651.30) | (388.57) | |
EV/EBIT |
18.58 | 18.48 | 22.98 | 12.76 | |
Capex to Sales |
0.01 | 0.01 | 1.00 | (1.26) | |
Price to Operating Income |
15.37 | 14.91 | 17.20 | 11.66 | |
| Other line items | |||||
Average Receivables |
386.08 | 381.31 | 374.86 | 315.89 | |
Average Payables |
21.15 | 17.09 | 15.57 | 13.88 | |
Average Inventory |
159.32 | 160.17 | 159.17 | 158.60 | |
Average Assets |
2,315.65 | 2,434.63 | 2,294.40 | 2,169.63 | |
Average Common Equity |
238.15 | 350.95 | 206.32 | 478.31 |
Columns are period end dates